Lichen planus responding to efalizumab - 12/08/11
Doi : 10.1016/j.jaad.2006.10.957
Reprint requests: Markus Böhm, MD, Department of Dermatology, University of Münster, Von Esmarch-Str. 58, D-48149 Münster, Germany.Münster, Germany
Abstract |
Lichen planus (LP) is a common inflammatory skin disorder of unknown origin. When generalized and relapsing, treatment of LP can be a challenge. We present a patient with widespread and relapsing generalized LP who was treated with efalizumab for 3 months. Both pruritus and the skin lesions responded promptly to this biologic. In accordance with the previously reported efficacy in oral erosive LP, efalizumab may be a promising novel future treatment option for patients with cutaneous LP.
Le texte complet de cet article est disponible en PDF.Plan
| Funding sources: None. Conflicts of interest: None declared. |
© 2007
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 56 - N° 5S
P. S92-S93 - mai 2007 Retour au numéro
Article précédent
- The expanding spectrum of Galli–Galli disease
- Laila El Shabrawi-Caelen, Arno Rütten, Helmut Kerl
- Bullous pemphigoid positive for anti-BP180 and anti-laminin 5 antibodies in a patient with graft-vs-host disease
- Rieko Izumi, Manabu Fujimoto, Norihito Yazawa, Hiroko Nakashima, Nobuko Asashima, Rei Watanabe, Yoshihoro Kuwano, Mineo Kurokawa, Takashi Hashimoto, Kunihiko Tamaki
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?